Systems and methods for delivery of a therapeutic agent
AssigneeThe Foundry, LLC
InventorsMark E. Deem, Hanson Gifford
Life of this patent
Estimating the term…
Abstract
Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
Claims35
A method for treating a neuromuscular spasm in a targeted region of mammalian tissue, said method comprising:
- delivering an active neurotoxin fragment consisting of a light chain of the neurotoxin throughout the targeted region;
- and
- focusing energy on membranes of cells within the target region under conditions which cause a reversible poration in said cell membranes to permit entry of the active fragment into the cytosols of said cells, wherein cells within the targeted region which do not receive focused energy are not porated and do not receive active fragments into their cytosols.
A method of treating a respiratory ailment, comprising:
- delivering a non-toxic therapeutically effective amount of a neurotoxin fragment consisting of BoNT-LC throughout a targeted region of the respiratory system;
- and
- permeabilizing the membranes of some but not all cells within the region to allow entry of the BoNT-LC into the permeabilized cells only.
A method for treating a respiratory ailment in a patient, the method comprising:
- delivering an active neurotoxin fragment consisting of a light chain of the neurotoxin throughout a targeted region of the respiratory system of the patient;
- and
- focusing energy to some but not all cells in the targeted region under conditions which cause a reversible poration in the cell membranes which receive the energy to permit entry of the active fragment into cytosols of the cells which receive the energy but not to cells within the targeted region which do not receive the energy.
Dependencies are inferred from the claim text.